Fluxion Biosciences Inc.

San Francisco, CA, United States

Fluxion Biosciences Inc.

San Francisco, CA, United States
SEARCH FILTERS
Time filter
Source Type

— According to Stratistics MRC, the Global Circulating Tumor Cells Market is accounted for $4.41 billion in 2015 and is expected to reach $17.96 billion by 2022 growing at a CAGR of 19.2 % from 2015 to 2022. The rising demand for high Benefit-Cost Ratio (BCR) associated with CTCs prognostic technology is the major factor boosting the market growth. Furthermore, advancements in biomedical imaging and bioengineering technology are some of the key factors driving the market. However, high cost associated with the diagnosing and reluctance among people towards adopting highly developed prognostic technologies inhibit the market growth. The recent trends in global Circulating Tumor Cells are strengthening distribution network of CTCs prognostic technologies in emerging economies and the technical advancement of CTCs-based customized medicines. Tumor cell detection is the foremost product segment primarily due to the advantages related with therapeutic monitoring and high procedure prices. North America region is expected to witness highest growth rate during the forecast period due to increasing demand in number of research projects. In addition, the U.S. Government also supports research by funding various institutes, which grant research funds. Some of the key players in the market include Adnagen AG, Advanced Cell Diagnostics, Apocell, Aviva Biosciences, Biocep Ltd., Biocept Inc., Biofluidica, Canopus Biosciences, CellTraffix Inc., Clearbridge BioMedics, Creatv Microtech Inc., Cynvenio Biosystems Inc. , Epic Biosciences, Fluxion Biosciences., Greiner Bio-One GmbH, Ikonisys Inc., IV Diagnostics Inc., Janssen Diagnostics, Miltenyi Biotech and Nanostring Technologies Inc. Regions Covered: North America US Canada Mexico Europe Germany France Italy UK Spain Rest of Europe Asia Pacific Japan China India Australia New Zealand Rest of Asia Pacific Rest of the World Middle East Brazil Argentina South Africa Egypt Major Points From Table Of Contents: Executive Summary Preface Market Trend Analysis Porters Five Force Analysis Key Developments Company Profiling About Us: Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients. For more information, please visit http://www.orbisresearch.com/reports/index/circulating-tumor-cells-global-market-outlook-2015-2022


SAN FRANCISCO, Feb. 27, 2017 /PRNewswire/ -- Fluxion Biosciences announced today that Genetracer Biotech of Santander, Spain has been appointed as a Certified Service Provider for Fluxion's IsoFlux CTC Liquid Biopsy System. The IsoFlux system will be used in Genetracer Biotech's novel...


SAN FRANCISCO, Nov. 4, 2016 /PRNewswire/ -- Fluxion Biosciences announced today the release of a second generation of its IonFlux automated patch clamp family of products. IonFlux Mercury will replace and update the existing IonFlux product family. While IonFlux systems were previously...


Apparatus and methods are provided for analysis of individual particles in a microfluidic device. The methods involve the immobilization of an array of particles in suspension and the application of experimental compounds. Such methods can also include electrophysiology studies including patch clamp recording, electroporation, or both in the same microfluidic device. The apparatus provided includes a microfluidic device coupled to a multi-well structure and an interface for controlling the flow of media within the microchannel device.


The invention discloses diagnostic techniques based on single cell genomics, consisting of obtaining a blood sample, enriching a sub-population of cells present in the blood sample, sequestering individual cells or group of cells from the blood sample, obtaining sequencing data from the sequestered cells or group of cells, using genetic variant information to determine the provenance of the cells, and genetically analyzing the cells of the correct provenance to provide a diagnostic readout. Using the cell-based testing techniques of the invention, the number of false positives is greatly reduced when compared to cell-free DNA (cfDNA) based traditional testing techniques. The invention may be effectively employed for non-invasive prenatal (NIPT) diagnostics, oncological testing and other diagnostic procedures.


Patent
Fluxion Biosciences Inc. | Date: 2011-07-14

Methods, microfluidic devices, and instruments for magnetic separation of particles from a fluid are described. Examples include microfluidic devices having a removable portion. Examples include microfluidic devices having one or more regions of reduced fluid velocity. Examples further including instruments having pneumatic interfaces. Examples further includes instruments having controllable magnets, imaging components, or combinations thereof.


Apparatus and methods are provided for analysis of individual particles in a microfluidic device. The methods involve the immobilization of an array of particles in suspension and the application of experimental compounds. Such methods can also include electrophysiology studies including patch clamp recording, electroporation, or both in the same microfluidic device. The apparatus provided includes a microfluidic device coupled to a multi-well structure and an interface for controlling the flow of media within the microchannel device.


Apparatus and methods are provided for analysis of individual particles in a microfluidic device. The methods involve the immobilization of an array of particles in suspension and the application of experimental compounds. Such methods can also include electrophysiology studies including patch clamp recording, electroporation, or both in the same microfluidic device. The apparatus provided includes a microfluidic device coupled to a multi-well structure and an interface for controlling the flow of media within the microchannel device.


SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--In advance of the 2015 American Society of Clinical Oncology Annual meeting, Fluxion Biosciences, Inc. and Swift Biosciences, Inc. announced a new workflow for oncology clinical research designed to detect somatic mutations from a routine blood draw. The jointly-developed workflow utilizes Fluxion’s IsoFlux™ System for circulating tumor cell (CTC) enrichment and Swift’s Accel-Amplicon™ technology for high sensitivity variant detection using low starting inputs. Liquid biopsies represent a major breakthrough in the ability to detect molecular changes in tumor progression without the need for a tissue biopsy. They offer the potential to characterize cancer in real time using only a routine blood draw, enabling targeted therapies to be used simultaneously monitoring for response and resistance. Until recently, this approach has been limited by the available amount of tumor DNA that can be recovered from peripheral blood samples. The IsoFlux System enriches rare tumor cells circulating in the blood using a combination of epithelial and mesenchymal markers, and delivers them at high purity for molecular analysis. Swift’s Accel-Amplicon 56G Oncology Panel provides sensitive mutation detection across 56 cancer-related genes using very low starting DNA inputs from the IsoFlux System, making this combination of technologies especially appropriate for liquid biopsy samples. “We’re pleased to be working with Swift on this application for translational oncology research,” said Michael Schwartz, VP Marketing at Fluxion. “We expect the combination of blood-based tumor DNA enrichment and broad tumor gene coverage to be put to good use by the types of institutions that are pursuing diagnostic strategies based on liquid biopsies.” “This workflow is a wonderful example of how innovators can collaborate to produce advanced tools for oncology research,” noted David Olson, CEO at Swift Biosciences. “Fluxion's CTC enrichment is a great pairing with our 56G Oncology Panel, and we are pleased that our respective technologies can be used together to shine new light on cancer biology.” The combined workflow begins with a standard blood draw and proceeds to CTC enrichment using epithelial and mesenchymal antibodies. The captured CTCs undergo DNA extraction and purification without the need for whole genome amplification. The genomic DNA then goes through target enrichment using the 56G Oncology Panel and library preparation for Illumina sequencers. The resulting data utilizes a custom bioinformatics pipeline designed to identify low frequency variants from liquid biopsy samples. The complete workflow is described in an application note and the products involved are available from Fluxion and Swift. For more information, please visit: www.fluxionbio.com and www.swiftbiosci.com. Fluxion Biosciences brings the power of cellular analysis to the benchtop with advanced tools to automate complex assays. The company’s IsoFlux System enables translational oncology research using a non-invasive liquid biopsy. This platform utilizes high-sensitivity circulating tumor cell (CTC) collection to facilitate broad-based genomic analysis using tools such as Next Generation Sequencing (NGS). This approach provides a more comprehensive look at the disease status, as compared to alternative approaches that only look at limited panels of known mutations. Fluxion’s other products, the BioFlux System and IonFlux System, have helped hundreds of research institutions and pharmaceutical companies around the world advance their cellular research and drug discovery. Swift Biosciences is developing innovative and enabling technologies for genomics research. The company’s Accel-NGS product portfolio brings unique capabilities to improve the efficiency and quality of (NGS) sample preparation across multiple applications. The Accel-NGS library preparation kits offer superior sequence coverage metrics, even from challenging samples, and can generate PCR-free libraries for whole genome sequencing from as little as 10ng of genomic input. The Accel-Amplicon products encompass multiple panels that include 56G, a stand-alone TP53 panel, and custom panels across multiple genomes. Swift Biosciences also offers kits for bisulfite converted DNA for methylation sequencing and a product for single-stranded DNA, ideal for viral and phage metagenomes.


SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Fluxion Biosciences announced the introduction of the IsoFlux™ EMT Enrichment Kit for the isolation of rare circulating tumor cells (CTCs) from blood samples. The new kit works with the IsoFlux System instrument and specifically targets cells with both epithelial and mesenchymal properties. This represents a breakthrough in liquid biopsy approaches since the mesenchymal properties have typically not been addressed in other capture systems. The IsoFlux EMT Enrichment Kits are available for immediate use through the IsoFlux Discovery Services program, with kit shipments to IsoFlux customers starting in the third quarter of 2015. CTCs enable access to tumor material without the need for a surgical biopsy. They possess the key advantage of being able to be preferentially enriched over the background blood cells, making it possible to analyze them using molecular methods such as Next Generation Sequencing (NGS). Tumor cell recovery is linked to the capture antibodies chosen in the enrichment process. Epithelial Cell Adhesion Molecular (EpCAM) antibodies have long been the default capture marker, but it is understood now that CTCs lose their EpCAM expression as they transition to a mesenchymal state. The IsoFlux EMT Enrichment Kit incorporates the EpCAM antibody as well as a proprietary cocktail of EMT-specific antibodies to increase the overall capture of all types of CTCs. The initial analytical and clinical validation demonstrated notable increase in tumor cell capture. “For several years now, the leading cancer scientists across the world have presented research on the dynamic changes in surface marker expression of cancer cells,” said Michael Schwartz, VP of Marketing at Fluxion. “We developed the IsoFlux EMT Enrichment Kit to provide a more comprehensive, turnkey solution for CTC capture that covers both epithelial and mesenchymal presentations.” Like the other IsoFlux enrichment kits, the IsoFlux EMT Enrichment Kit includes the IsoFlux microfluidic cartridges, magnetic beads, running reagents, and proprietary cocktail of capture antibodies. For more information, please visit: http://fluxionbio.com/isoflux. Fluxion Biosciences provides cellular analysis tools for use in critical life science, drug discovery, and diagnostic applications. Products include the BioFlux™ System for studying cellular interactions, the IonFlux™ System for high throughput patch clamp measurements, and the IsoFlux™ System for circulating tumor cell analysis. Fluxion’s systems are designed to replace laborious and difficult assays by providing intuitive, easy-to-use instruments for cell-based analysis. For more information about Fluxion Biosciences, visit www.fluxionbio.com.

Loading Fluxion Biosciences Inc. collaborators
Loading Fluxion Biosciences Inc. collaborators